$IKT 8-K SEC Filings

Filed On	Filing
20 Oct 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure WILMINGTON, Del., October 20, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial H...
08 Sep 2026	8-K: Regulation FD Disclosure Disclaimer This presentation contains information that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Inhibikase Therapeutics, Inc. (the “Company” or “w...
26 Aug 2026	8-K: Changes in Registrant's Certifying Accountant
11 Aug 2026	8-K: Results of Operations and Financial Condition
29 Jul 2026	8-K: Unregistered Sales of Equity Securities
23 Jul 2026	8-K: Regulation FD Disclosure
14 Jul 2026	8-K: Other Events
29 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
12 May 2026	8-K: Results of Operations and Financial Condition
07 Apr 2026	8-K: Regulation FD Disclosure
26 Mar 2026	8-K: Results of Operations and Financial Condition
19 Dec 2025	8-K: Other Events
21 Nov 2025	8-K: Entry into a Material Definitive Agreement; Other Events
20 Nov 2025	8-K: Other Events
14 Nov 2025	8-K: Results of Operations and Financial Condition
14 Aug 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
30 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
14 May 2025	8-K: Results of Operations and Financial Condition
14 Apr 2025	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
27 Mar 2025	8-K: Results of Operations and Financial Condition

Comments